Ignite Creation Date:
2024-05-06 @ 1:59 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04186052
Status:
UNKNOWN
Last Update Posted:
2019-12-04
First Post:
2019-11-05
Brief Title:
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive rr Multiple Myeloma
Sponsor:
PersonGen BioTherapeutics Suzhou Co Ltd
Organization:
PersonGen BioTherapeutics Suzhou Co Ltd
Study Overview
Official Title:
Clinical Study Protocol for Targeting BCMA Autochimeric Antigen Receptor T Cell Infusion One-arm Single-center Open-label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA-positive RelapsedRefractory Multiple Myeloma
Status:
UNKNOWN
Status Verified Date:
2019-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple myeloma is a kind of hematological malignancy caused by the proliferation of malignant clonal plasma cells In recent years the emergence of new therapeutic drugs such as bortezomib and lenalidomide has significantly improved the therapeutic effect of mm However due to the presence of myeloma stem cells most patients will inevitably relapse and die With the development of biomedicine and immunology immunotherapy with chimeric antigen receptor modified T cells has attracted great attention for its amazing efficacy CAR-T cells carry receptors that can specifically recognize myeloma associated antigens and their killing effect is not limited by MHC molecules B-cell mature antigen is only expressed on the surface of B cells in germinal center malignant and normal plasma cells not on other normal human tissues and CD34 hematopoietic stem cells It is a relatively specific high expression on the surface of myeloma cells which is an ideal target for MM immunotherapy The aim of this study was to investigate the efficacy and safety of BCMA targeted T cell infusion in the treatment of BCMA positive multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None